Q1 EPS Forecast for Ovid Therapeutics Raised by Analyst

Ovid Therapeutics Inc. (NASDAQ:OVID) – Analysts at Wedbush lifted their Q1 2025 earnings estimates for shares of Ovid Therapeutics in a note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their previous forecast of ($0.15). Wedbush currently has a “Outperform” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.51) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.88 EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.19 million.

Other research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Ovid Therapeutics in a research note on Wednesday, December 4th. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 target price for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $3.20.

Ovid Therapeutics Price Performance

Shares of NASDAQ OVID opened at $0.47 on Monday. Ovid Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $3.45. The stock has a market capitalization of $33.10 million, a price-to-earnings ratio of -0.99 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. The business has a 50-day moving average of $0.64 and a 200-day moving average of $0.95.

Institutional Investors Weigh In On Ovid Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of Ovid Therapeutics in the fourth quarter valued at approximately $7,012,000. Kennedy Capital Management LLC boosted its stake in Ovid Therapeutics by 1.1% in the 4th quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock valued at $1,443,000 after purchasing an additional 17,402 shares during the period. Geode Capital Management LLC grew its holdings in Ovid Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock valued at $1,555,000 after buying an additional 14,816 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Ovid Therapeutics in the 4th quarter valued at $934,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Ovid Therapeutics by 50.2% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company’s stock worth $881,000 after buying an additional 315,126 shares during the period. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.